Market Closed -
Nasdaq
04:00:00 2024-05-22 pm EDT
|
5-day change
|
1st Jan Change
|
2.16
USD
|
-2.26%
|
|
-12.20%
|
-45.18%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
807.7
|
163.5
|
433.9
|
257.5
|
-
|
-
|
Enterprise Value (EV)
1 |
216.3
|
-208.5
|
233.2
|
67.74
|
-3.058
|
-70.54
|
P/E ratio
|
-1.36
x
|
-0.67
x
|
-2.18
x
|
-2.45
x
|
-13.2
x
|
5.84
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
1.48
x
|
0.79
x
|
0.6
x
|
EV / Revenue
|
-
|
-
|
-
|
0.39
x
|
-0.01
x
|
-0.16
x
|
EV / EBITDA
|
-0.95
x
|
0.9
x
|
-1.1
x
|
-0.91
x
|
-0.12
x
|
-1.04
x
|
EV / FCF
|
-
|
-
|
-1.34
x
|
-0.41
x
|
0.14
x
|
-1.05
x
|
FCF Yield
|
-
|
-
|
-74.5%
|
-244%
|
693%
|
-95.4%
|
Price to Book
|
1.45
x
|
0.46
x
|
2.45
x
|
1.44
x
|
1.05
x
|
0.84
x
|
Nbr of stocks (in thousands)
|
111,252
|
108,982
|
110,115
|
119,221
|
-
|
-
|
Reference price
2 |
7.260
|
1.500
|
3.940
|
2.160
|
2.160
|
2.160
|
Announcement Date
|
3/30/22
|
3/23/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
174.2
|
325.6
|
428.7
|
EBITDA
1 |
-226.9
|
-230.6
|
-212.3
|
-74.61
|
26.47
|
67.83
|
EBIT
1 |
-226.9
|
-230.7
|
-212.8
|
-117.9
|
-22.83
|
52.8
|
Operating Margin
|
-
|
-
|
-
|
-67.69%
|
-7.01%
|
12.32%
|
Earnings before Tax (EBT)
1 |
-226.8
|
-241.3
|
-198.6
|
-110.2
|
-15.7
|
57.8
|
Net income
1 |
-226.8
|
-241.3
|
-198.6
|
-110.2
|
-15.7
|
57.8
|
Net margin
|
-
|
-
|
-
|
-63.29%
|
-4.82%
|
13.48%
|
EPS
2 |
-5.320
|
-2.230
|
-1.810
|
-0.8800
|
-0.1633
|
0.3700
|
Free Cash Flow
1 |
-
|
-
|
-173.8
|
-165
|
-21.2
|
67.3
|
FCF margin
|
-
|
-
|
-
|
-94.73%
|
-6.51%
|
15.7%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
99.22%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
116.44%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/22
|
3/23/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
6
|
45.13
|
113.3
|
92
|
38.5
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-38.95
|
-53.75
|
-42.94
|
-76.63
|
-45.97
|
-54.9
|
-47
|
1.5
|
-
|
-
|
EBIT
1 |
-83.09
|
-100.7
|
-51.75
|
-47.33
|
-48.21
|
-39.07
|
-53.88
|
-43.06
|
-76.75
|
-46.09
|
-49.33
|
-32.53
|
10.07
|
-11.5
|
-46.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-822.22%
|
-72.08%
|
8.88%
|
-12.5%
|
-120.52%
|
Earnings before Tax (EBT)
1 |
-83.04
|
-100.7
|
-50.99
|
-45.09
|
-44.57
|
-35.32
|
-50.23
|
-39.44
|
-73.65
|
-43.5
|
-47.47
|
-31
|
11.93
|
-8.9
|
-43.8
|
Net income
1 |
-83.04
|
-100.7
|
-50.99
|
-45.09
|
-44.57
|
-35.32
|
-50.23
|
-39.44
|
-73.65
|
-43.5
|
-47.47
|
-31
|
11.93
|
-8.9
|
-43.8
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-791.11%
|
-68.69%
|
10.53%
|
-9.67%
|
-113.77%
|
EPS
2 |
-0.7600
|
-0.9300
|
-0.4700
|
-0.4200
|
-0.4100
|
-0.3200
|
-0.4600
|
-0.3600
|
-0.6700
|
-0.3800
|
-0.3633
|
-0.2567
|
0.0767
|
-0.0500
|
-0.2600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/22
|
5/13/22
|
8/15/22
|
11/10/22
|
3/23/23
|
5/11/23
|
8/10/23
|
11/9/23
|
3/28/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
591
|
372
|
201
|
190
|
261
|
328
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-174
|
-165
|
-21.2
|
67.3
|
ROE (net income / shareholders' equity)
|
-81.8%
|
-52.8%
|
-74.5%
|
-0.49%
|
34.7%
|
24.2%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
5.020
|
3.260
|
1.610
|
1.500
|
2.050
|
2.560
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
0.62
|
8.2
|
11.8
|
12.8
|
Capex / Sales
|
-
|
-
|
-
|
4.71%
|
3.62%
|
2.99%
|
Announcement Date
|
3/30/22
|
3/23/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
2.16
USD Average target price
9.225
USD Spread / Average Target +327.08% Consensus |
1st Jan change
|
Capi.
|
---|
| -45.18% | 258M | | +9.99% | 115B | | +12.01% | 106B | | -3.07% | 24.69B | | -0.64% | 21.97B | | -4.64% | 19.27B | | -6.90% | 17.56B | | -39.36% | 17.32B | | +5.82% | 14.03B | | +33.05% | 12.13B |
Bio Therapeutic Drugs
|